Gaucher disease treatment compared: enzyme replacement vs substrate reduction, every US drug’s label, dosing, limits, and where new Infilbray fits.
Last updated: November 19, 2026
Gaucher disease has two drug strategies. Enzyme replacement therapy (Cerezyme, VPRIV, Elelyso) infuses the missing enzyme, typically every two weeks. Substrate reduction therapy (Cerdelga, miglustat, and now Infilbray) is oral and cuts production of the lipid that builds up. Only Infilbray is labeled for neurological disease.
Scope: US approved Gaucher drugs as of November 19, 2026, compared on mechanism, indication, dosing and label limits, plus a decision framework. Label details come from FDA and DailyMed prescribing information.
What is Gaucher disease?
Gaucher disease is an inherited lysosomal storage disorder in which a fatty substance, glucosylceramide, accumulates in cells because the enzyme that breaks it down (glucocerebrosidase) does not work well. The buildup drives an enlarged spleen and liver, low blood counts and, in some forms, damage to the nervous system.
MedlinePlus Genetics (NIH) estimates Gaucher disease “occurs in 1 in 50,000 to 100,000 people in the general population,” and that Type 1 affects 1 in 500 to 1,000 people of Ashkenazi Jewish heritage. That makes it rare enough for orphan economics and common enough to support several branded products in the US.
What are the three types of Gaucher disease?
Clinicians split Gaucher disease into three types based on whether, and how fast, the nervous system is involved. The type decides which drugs can help.
| Type | Also called | Nervous system | Course (per MedlinePlus) |
|---|---|---|---|
| Type 1 | Non neuronopathic | Usually not affected | Most common form in the US and Europe |
| Type 2 | Acute neuronopathic | Severely affected | Life threatening problems beginning in infancy |
| Type 3 | Chronic neuronopathic | Affected | Worsens more slowly than Type 2 |
Until this week, every US Gaucher drug was aimed at the systemic disease. That left Types 2 and 3 with no approved option for the brain. Sanofi’s Infilbray, approved November 18, 2026, changed that for Type 3.
How does enzyme replacement therapy work?
Enzyme replacement therapy (ERT) supplies a manufactured version of glucocerebrosidase by intravenous infusion, usually every other week, so cells can clear the stored lipid. It is the longest standing Gaucher treatment and works on the spleen, liver and blood counts.
Its limit is size. ERT is a large protein that does not cross the blood brain barrier in useful amounts. NORD notes that ERT does not primarily address brain related problems because of the blood brain barrier. All three US ERTs now carry a boxed warning for hypersensitivity reactions including anaphylaxis.
How does substrate reduction therapy work?
Substrate reduction therapy (SRT) takes the opposite approach. Instead of adding enzyme to clear the lipid, an oral small molecule inhibits glucosylceramide synthase, the enzyme that makes the lipid in the first place. Less input means less buildup.
Because SRTs are small molecules, some can reach the brain. That is the design premise of venglustat (Infilbray), which Sanofi describes as acting across the blood brain barrier. The older SRTs, eliglustat and miglustat, are labeled only for Type 1 disease in adults.
Which Gaucher drugs are approved in the US?
Six products cover Gaucher disease in the US: three ERTs and three SRTs (counting miglustat once, though generics exist). Here is how their labels compare.
| Drug | Class | First US approval | Indication (summary) | Route and schedule |
|---|---|---|---|---|
| Cerezyme (imiglucerase), Sanofi | ERT | 1994 | Non CNS manifestations of Type 1 or Type 3, adults and children | IV; 2.5 units/kg three times a week up to 60 units/kg every two weeks |
| VPRIV (velaglucerase alfa), Takeda | ERT | 2010 | Long term ERT for Type 1 | IV; 60 units/kg every other week, 60 minute infusion |
| Elelyso (taliglucerase alfa), Pfizer | ERT | 2012 | Type 1, patients 4 years and older | IV; 60 units/kg every other week, 60 to 120 minute infusion |
| Zavesca (miglustat) and generics | SRT | 2003 | Adults with mild to moderate Type 1 for whom ERT is not an option | Oral; 100 mg three times a day |
| Cerdelga (eliglustat), Sanofi | SRT | 2014 | Adults with Type 1 who are CYP2D6 extensive, intermediate or poor metabolizers | Oral; 84 mg twice daily (once daily for poor metabolizers) |
| Infilbray (venglustat), Sanofi | SRT | 2026 | Neurological manifestations of Type 3, adults and children at least 15 kg | Oral; once daily |
Two updates make older comparisons out of date. Cerezyme’s label expanded in January 2026 to cover non CNS manifestations of Type 3 disease, per the FDA approval letter for supplement 123; Sanofi said the expansion relied on real world evidence from the ICGG Gaucher Registry. And Infilbray is the first drug labeled for the neurological side of any Gaucher type.
ERT vs SRT: what are the trade offs?
ERT has the longest track record and covers children and adults with systemic disease, but it means lifelong infusions and an anaphylaxis risk. SRT is a pill, but the older options are adult only, Type 1 only and carry their own label conditions.
| Factor | ERT | SRT |
|---|---|---|
| Mechanism | Replaces the missing enzyme | Reduces production of the stored lipid |
| Route | IV infusion, usually every two weeks | Oral, once to three times daily |
| Brain penetration | Not meaningful | Venglustat designed to cross; others not labeled for CNS |
| Pediatric use | Labeled for children (Cerezyme, Elelyso from age 4) | Infilbray only; Zavesca pediatric use not established |
| Key label warning | Boxed warning: hypersensitivity including anaphylaxis | Varies: ECG changes (Cerdelga), neuropathy and tremor (Zavesca), suicidal ideation (Infilbray) |
| Testing before use | Diagnosis of Gaucher type | CYP2D6 genotype for Cerdelga |
Why does Cerdelga need a CYP2D6 test?
Eliglustat is cleared mainly by the CYP2D6 liver enzyme, so how fast a patient metabolizes it changes drug levels. The Cerdelga label requires an FDA cleared CYP2D6 genotype test before treatment.
Extensive and intermediate metabolizers take 84 mg twice daily; poor metabolizers take 84 mg once daily. The label says ultrarapid metabolizers “may not achieve adequate concentrations” for a therapeutic effect, and no dose can be recommended when genotype is indeterminate. It also lists contraindications that depend on metabolizer status and on use with CYP2D6 and CYP3A inhibitors, plus a warning for ECG changes and potential cardiac arrhythmias.
When is miglustat used?
Miglustat is a second line option. Its label limits it to adults with mild to moderate Type 1 disease “for whom enzyme replacement therapy is not a therapeutic option,” for example because of allergy, hypersensitivity or poor venous access.
The dose is 100 mg three times a day, with reductions for tremor, diarrhea or kidney impairment. Warnings cover peripheral neuropathy, tremor, diarrhea and weight loss, and lower platelet counts, and the label calls for neurological evaluations at baseline and every six months. Several generic versions are listed on DailyMed.
What does Infilbray change?
Infilbray is the first drug approved for neurological manifestations of Type 3 Gaucher disease. In the Phase 3 LEAP2MONO trial, 43 patients aged 12 and older were randomized to oral venglustat or imiglucerase infusions, and venglustat showed statistically significant superiority on a combined ataxia and cognition endpoint at week 52, per Sanofi.
Its warnings cover suicidal ideation and behavior, lens opacification in pediatric patients and embryofetal toxicity. Sanofi has not disclosed price, dose in milligrams or how it should be combined with ERT. Our full breakdown of the approval is linked below.
Our framework: choosing between ERT and SRT
This is our decision checklist for clinicians, payers and market analysts. It is not medical advice; treatment decisions belong to the patient and their specialist.
- Confirm the type. Type 1 opens every systemic option. Type 3 now points to Cerezyme for systemic disease and Infilbray for neurological disease. Type 2 still has no labeled therapy for its neurological course.
- Check age and weight. Older SRTs are adult only. Infilbray starts at 15 kg. ERTs cover children.
- Genotype CYP2D6 before Cerdelga. Ultrarapid and indeterminate metabolizers are not candidates.
- Review heart risk and interacting drugs before eliglustat, given its ECG warning and inhibitor contraindications.
- Weigh infusion burden. Every two weeks for life is a real cost in time, access and venous health.
- Screen mood and plan eye exams for Infilbray, given its suicidal ideation and pediatric lens warnings.
- Plan for anaphylaxis on any ERT, which all carry a boxed warning.
- Map coverage. Patients on two products, such as an ERT plus Infilbray, will test prior authorization rules.
What to watch next
- Full Infilbray prescribing information, dose and FDA review documents
- Infilbray price and launch timing
- EU and Japan decisions on venglustat for Type 3 disease
- Venglustat in Fabry disease, where PERIDOT missed its primary endpoint and CARAT continues, per Sanofi
- Gene therapy and brain penetrant programs aimed at neuronopathic Gaucher disease and other lysosomal storage disorders
Frequently asked questions
What is the main treatment for Gaucher disease?
Enzyme replacement therapy given by IV infusion, usually every two weeks, is the longest standing treatment. Oral substrate reduction therapy is an alternative for some adults with Type 1 disease.
What is the difference between ERT and SRT?
ERT replaces the missing enzyme so cells can clear stored lipid. SRT blocks the enzyme that makes the lipid, so less builds up. ERT is infused; SRT is a pill.
Which Gaucher drugs are oral?
Cerdelga (eliglustat), Zavesca (miglustat) and its generics, and Infilbray (venglustat). All three are substrate reduction therapies.
Is there a treatment for neurological Gaucher disease?
Yes, as of November 18, 2026. The FDA approved Infilbray for neurological manifestations of Type 3 Gaucher disease. No drug is labeled for the neurological course of Type 2.
Can ERT treat the brain in Gaucher disease?
No. ERT is a large protein that does not cross the blood brain barrier in useful amounts. Cerezyme’s Type 3 indication is limited to non CNS manifestations.
Why do Cerezyme, VPRIV and Elelyso have boxed warnings?
All three carry boxed warnings for hypersensitivity reactions including anaphylaxis, per their labels. The Cerezyme label notes anaphylaxis can occur early in treatment or after extended use.
Who can take Cerdelga?
Adults with Type 1 Gaucher disease who are CYP2D6 extensive, intermediate or poor metabolizers on an FDA cleared test. Ultrarapid metabolizers may not reach adequate levels.
Is miglustat a first line Gaucher treatment?
No. Its label limits it to adults with mild to moderate Type 1 disease for whom ERT is not an option, for example because of allergy or poor venous access.
Can children take Gaucher medicines?
Cerezyme is labeled for adults and children, and Elelyso for patients 4 and older. Infilbray covers children weighing at least 15 kg. Pediatric safety of Zavesca and Cerdelga has not been established.
How common is Gaucher disease?
MedlinePlus Genetics estimates 1 in 50,000 to 100,000 people overall, and Type 1 affects 1 in 500 to 1,000 people of Ashkenazi Jewish heritage.
Can patients switch from one ERT to another?
Yes. The VPRIV and Elelyso labels both give instructions for switching from imiglucerase at the same units per kg dose.
Sources
- Cerezyme prescribing information, revised January 2026, DailyMed (primary)
- FDA approval letter, Cerezyme supplement 123, January 2026 (primary): https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/020367Orig1s123ltr.pdf
- VPRIV prescribing information, DailyMed and FDA label 022575 (primary)
- Elelyso prescribing information, Pfizer and DailyMed (primary)
- Zavesca and generic miglustat prescribing information, DailyMed (primary)
- Cerdelga prescribing information, revised January 2024, DailyMed (primary)
- Sanofi, Infilbray US approval release, November 18, 2026 (primary): https://www.sanofi.com/en/media-room/press-releases/2026/2026-11-18-22-19-06-3406209
- Sanofi, LEAP2MONO results release, February 2, 2026 (primary): https://www.sanofi.com/en/media-room/press-releases/2026/2026-02-02-06-00-00-3229947
- MedlinePlus Genetics, Gaucher disease (attributed): https://medlineplus.gov/genetics/condition/gaucher-disease
- NORD, Gaucher disease (attributed): https://rarediseases.org/rare-diseases/gaucher-disease
Related coverage
- Sanofi’s Infilbray approved for neurological Type 3 Gaucher disease
- Boxed warning vs Warnings and Precautions: how FDA flags risk
- Biosimilar patent dance: why approval does not mean launch
- Gene therapy long term follow up: what FDA requires
- PDUFA dates explained
- BioMed Nexus company directory
Get the daily briefing on biotech, pharma and medtech: subscribe to BioMed Nexus.


